The first resistance analysis of bulevirtide — a lipopeptide drug for hepatitis delta — found zero viral mutations reducing drug sensitivity through 24 weeks, demonstrating a high barrier to resistance.
Zero resistance mutationsDeep sequencing and phenotypic testing of 21 non-responding patients found no amino acid changes associated with reduced bulevirtide sensitivity — a remarkably high barrier to resistance for an antiviral drug
What the researchers found
In the first-ever viral resistance analysis of bulevirtide (a lipopeptide entry inhibitor for hepatitis delta virus), no drug resistance was detected in any patient through 24 weeks of treatment. Deep sequencing of the drug's target regions found no amino acid changes associated with reduced sensitivity to bulevirtide — not in the 20 non-responders, not in the 1 patient with virologic breakthrough, and not in any baseline samples.
Phenotypic testing of 116 baseline samples showed similar bulevirtide susceptibility (EC50 values) across responders, partial responders, and non-responders regardless of any HBV or HDV genetic variations present. This demonstrates that bulevirtide has a high barrier to resistance, and that non-response to treatment is caused by other unknown mechanisms — not viral escape from the drug.
Why it matters
Hepatitis delta is the most severe form of viral hepatitis, and bulevirtide is the first drug specifically approved to treat it. Drug resistance is the biggest fear with any antiviral therapy — if the virus mutates to evade the drug, treatment fails. This study shows bulevirtide has a remarkably high genetic barrier to resistance, making it suitable for long-term use. Since hepatitis delta requires prolonged treatment, this resistance profile is crucial for clinical confidence.
The numbers in context
n=21 analyzed (20 non-responders + 1 virologic breakthrough) · 116 baseline samples phenotyped · 24-week treatment period · 0 resistance mutations detected · EC50 values similar across all response categories · Variants found in 14 patients — none reduced drug sensitivity
How the study worked
Researchers performed deep sequencing on the bulevirtide-target regions of HBV PreS1 and HDV HDAg genes at baseline and week 24 in 21 patients from the phase II MYR202 and phase III MYR301 trials who either didn't respond adequately or had virologic breakthrough. In vitro phenotypic susceptibility testing measured bulevirtide EC50 values across 116 baseline samples from patients with all response categories.
Who was studied
21 patients with chronic hepatitis delta from phase II/III bulevirtide trials (non-responders and virologic breakthrough cases)
What this study cannot tell us
The analysis covered only 24 weeks — longer treatment periods could potentially select for resistance mutations not seen in this timeframe. Only 21 non-responder/breakthrough patients were analyzed by deep sequencing. The finding that non-response isn't caused by resistance raises new questions about what does cause it. This was a monotherapy analysis; combination therapy regimens may have different resistance dynamics.
How to read the evidence
This analysis draws from two well-designed clinical trials (phase II and III) and uses rigorous molecular methods including deep sequencing and in vitro phenotypic testing across 116 samples. Published in Journal of Hepatology, a top hepatology journal. The only limitation is the 24-week timeframe and relatively small non-responder sample.
When this study was published
Published in 2023, this is the first and most current resistance analysis for bulevirtide. As the drug is increasingly used in clinical practice, longer-term resistance surveillance data will follow.
The bigger picture
Bulevirtide represents a triumph of peptide-based drug design — it's derived from the PreS1 domain of hepatitis B surface antigen and blocks viral entry at the NTCP receptor. The finding that it has a high barrier to resistance validates its mechanism: blocking a host receptor (rather than a viral enzyme) may make it harder for the virus to evolve around the drug. This principle could guide the development of other peptide-based entry inhibitors for different viruses.
Questions still open
- If viral resistance doesn't explain non-response to bulevirtide, what other mechanisms allow hepatitis delta virus to persist during treatment?
- Will the high resistance barrier hold up over years of continuous treatment, as many hepatitis delta patients will require?
- Could bulevirtide's mechanism of blocking a host receptor (NTCP) rather than a viral target be applied to other viral diseases?
Common questions
What is bulevirtide and why is it important?
Why is it good news that no drug resistance was found?
Read the original research
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Journal of hepatology, 79(3), 657-665
Citation
Hollnberger, Julius; Liu, Yang; Xu, Simin; Chang, Silvia; Martin, Ross; Manhas, Savrina; Aeschbacher, Thomas; Han, Bin; Yazdi, Tahmineh; May, Lindsey; Han, Dong; Shornikov, Alex; Flaherty, John; Manuilov, Dmitry; Suri, Vithika; Asselah, Tarik; Lampertico, Pietro; Wedemeyer, Heiner; Aleman, Soo; Richards, Christopher; Mateo, Roberto; Maiorova, Evguenia; Cihlar, Tomas; Mo, Hongmei; Urban, Stephan. (2023). No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.. Journal of hepatology, 79(3), 657-665. https://doi.org/10.1016/j.jhep.2023.04.027